Answers are grounded in this paper and cite their sources.
Background Bulky, symptomatic tumors can compromise performance and nutritional status and may limit the immediate feasibility of systemic anticancer therapy. Stereotactic centralized ablative radiation therapy (SCART) enables focal delivery of ablative doses within larger tumor volumes with reduced doses in surrounding normal tissues. However, clinical experience with SCART followed by hypofractionated radiotherapy (HFRT) for rapid debulking of bulky symptomatic metastatic tumors remains limited, particularly in patients with temporarily limited treatment options. This case report describes the feasibility and clinical course of SCART followed by HFRT in a patient with bulky symptomatic metastatic non-small cell lung cancer (NSCLC). Case presentation A 67-year-old man with metastatic squamous NSCLC presented with a rapidly enlarging sternal metastasis 100 mm in maximum diameter, severe pain, dyspnea, and difficulty eating. His Karnofsky performance status (KPS) score was 70, accompanied by marked anemia, hypoalbuminemia, and high nutritional risk. Because the patient initially declined systemic anticancer therapy, SCART was administered to the sternal metastasis (36 Gy in 3 fractions), followed by HFRT (45 Gy in 15 fractions). The primary lung tumor was treated concurrently with HFRT (30 Gy in 10 fractions). Three weeks after radiotherapy, the maximum diameters of the sternal metastasis and primary tumor had decreased from 100 and 67 mm to 46 and 40 mm, respectively, with concomitant alleviation of symptoms. The patient subsequently received systemic therapy with paclitaxel, carboplatin, and penpulimab. No grade ≥3 acute radiation-related toxicity was observed during follow-up. Conclusion In this patient, SCART followed by HFRT, together with nutritional support, was associated with rapid local tumor regression and symptomatic improvement, facilitating the subsequent initiation of systemic anticancer therapy. Although the independent contribution of SCART cannot be determined from this single case, rapid local tumor debulking may create opportunities for subsequent systemic therapy in selected patients with bulky symptomatic metastatic disease and temporarily limited treatment options. Nevertheless, the short follow-up precludes conclusions regarding durable local control, late toxicity, and long-term quality-of-life improvement. Further studies are warranted to evaluate the efficacy and safety of this sequential treatment strategy.
No takes yet. Share an insight, caveat, or question.
Xing et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: